Pfizer is undervalued, trading just over 8x 2026 earnings, with improving dividend yield and core business fundamentals.

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.” In an investor presentation (PDF) Tuesday, the company made ...

Former New York Times journalist Alex Berenson told “Pod Force One” in the latest episode, released Wednesday, that the ...

The ability to inoculate young children against COVID-19 in the U.S. may be diminished this fall as the FDA weighs whether to renew the emergency green light for the vaccine currently cleared in the ...

These high-yield stocks have long track records of dividend consistency and growth.

State-by-State Maps and Distribution Data Why Can’t I Get A COVID-19 Booster Shot If I’ve Been Vaccinated With Moderna or J&J ...